Modalis Therapeutics Corporation

Business Details

A drug discovery venture engaged in the research and development of gene therapies primarily targeting rare muscle diseases, using its proprietary platform technology "CRISPR-GNDM® (non-cutting CRISPR technology)." The company employs a "hybrid model" combining a collaborative model (licensing out to partners) and an in-house model (self-led development). Currently, business revenue is zero, and R&D expenses together with general administrative expenses constitute all costs. The company holds multiple in-house pipeline programs and continues development with the transition of MDL-101 to clinical stage as its top priority.

Recent Overview

Loss nearly halved year-on-year; MDL-101 continues preparations for clinical transition with launch of GLP toxicity study pilot

Operating loss for the first quarter of FY2026 (ending December 2026) (January to March 2026) was ¥343 million, an improvement of approximately 46% from the same period of the prior year (¥633 million). This was mainly due to a significant decrease in R&D expenses from ¥572 million to ¥294 million. MDL-101 has begun a pilot study toward a repeat GLP toxicity study, and initial results regarding in vivo behavior following administration have generally been in line with expectations. The rebuilding of the quality evaluation process is also underway. MDL-202 successfully constructed a novel molecule through joint research with a U.S. biotech company and this was presented at ASGCT in May 2025. Through the exercise of share subscription rights with exercise price adjustment provisions, capital stock and capital surplus each increased by ¥161,739 thousand. As a subsequent event, an additional 3,780,000 shares were issued in April 2026, expanding the total number of shares issued to 96,334,098. Cash and deposits were maintained at ¥2,812 million, and the company has determined that operating funds for the coming year have been secured.

Key Products

Growth Drivers

• Confirmation of a clear survival extension effect for MDL-101 in IND-enabling studies through comparison with control groups (continued support for pharmacological efficacy)
• Improved development precision and reproducibility toward clinical transition through the start of the GLP toxicity study pilot study for MDL-101
• Successful construction of a novel molecule for MDL-202 using muscle-specific capsid technology and strong interest from the expert community at ASGCT
• Acquisition of research and development support funding based on the strategic alliance with SOLVE FSHD (related to MDL-103)
• Expanding access to novel enabling technologies through multiple joint research collaborations, including with JCR Pharmaceuticals
• Securing R&D funding through continued exercise of share subscription rights with exercise price adjustment provisions (capital stock and capital surplus each increased by ¥161,739 thousand during the first quarter, with a further increase of ¥101,552 thousand each by the end of April)
• Improved capital efficiency and maintenance of cash balance through a substantial reduction in R&D expenses (down approximately 49% year-on-year)

Risks

• Business revenue has remained at zero, and continuing operating losses and negative operating cash flow give rise to a situation raising material doubt about the going concern assumption (although the notes conclude that no material uncertainty exists)
• Continued risk of further delay in the timing of IND application and clinical transition due to additional verification and pilot studies related to the GLP toxicity study for MDL-101
• Uncertainty in the development schedule until the rebuilding of the quality evaluation process (including review of the external vendor structure) is completed
• High uncertainty regarding the revenue outlook, to the extent that earnings forecasts for FY2026 (ending December 2026) are undisclosed as they cannot be reasonably estimated
• Risk of share dilution due to continued exercise of share subscription rights with exercise price adjustment provisions (expansion from 92,354,098 shares at the end of the first quarter to 96,334,098 shares by the end of April)
• Risk that changes in the external environment, including U.S. healthcare and drug pricing policy, may affect R&D activities and the approval process
• Continued uncertainty in the future fundraising environment due to limited recovery in investment sentiment toward the biotech and drug discovery sector
• Risk that macroeconomic factors such as tensions in the Middle East, energy price fluctuations, and exchange rate volatility may affect R&D expenses